A randomized phase 2 single blind study of temozolomide plus radiation therapy combined with nivolumab or placebo in newly diagnosed adult subjects with MGMT-methylated glioblastoma (BMS CA209-548)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
August 1, 2016
End Date
July 31, 2020
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
August 1, 2016
End Date
July 31, 2020